AMY VALENTINE: Open Payments
NPI 1922546589 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$984 in 40 payments from 10 companies in 2025. Trend: 2023 $837 · 2024 $1,351 · 2025 $984
Food & beverage: $984
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 22 | $380 |
| Boston Scientific Corporation | 3 | $311 |
| Medtronic, Inc. | 6 | $148 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| PFIZER INC. | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $11 |
Products named: LEQVIO, WATCHMAN Access System, SYMPLICITY G3, CDS - MCT/CEM Monitoring, NEXLETOL, AMVUTTRA, VERQUVO, Kerendia.
Industry payments across MS — which companies pay providers there.
